NEW YORK (360Dx) – DNA Diagnostics Center announced on Tuesday it is acquiring all the assets of male reproductive health company ContraVac.
Financial and other terms of the deal were not disclosed. ContraVac will relocate to DNA Diagnostics' headquarters in Fairfield, Ohio.
Based in Charlottesville, Virginia, ContraVac markets the SpermCheck Fertility, SpermCheck Vasectomy, and FertileCheck Fertility Gel. The SpermCheck family of products are at-home, US Food and Drug Administration-approved immunoassays for measuring sperm count. SpermCheck Fertility is for determining whether a man has fertile or subfertile sperm count. SpermCheck Vasectomy is for determining the success of a vasectomy.
DNA Diagnostics' "worldwide sales, marketing, and distribution networks will enable us to create global awareness of the frequency of male factor infertility, accounting for up to 50 percent of couple infertility, and increase the availability of SpermCheck Fertility for couples who have been trying to conceive without success," said ContraVac CEO Ed Leary, who will join DNA Diagnostics.
DNA Diagnostics provides DNA testing for paternity and family relationships, forensics, genetic traits of animals, and ancestry. In addition to its Ohio location, it has an office in London.